[go: up one dir, main page]

CN102584814A - Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane - Google Patents

Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane Download PDF

Info

Publication number
CN102584814A
CN102584814A CN2012100016087A CN201210001608A CN102584814A CN 102584814 A CN102584814 A CN 102584814A CN 2012100016087 A CN2012100016087 A CN 2012100016087A CN 201210001608 A CN201210001608 A CN 201210001608A CN 102584814 A CN102584814 A CN 102584814A
Authority
CN
China
Prior art keywords
benzyl
azabicyclo
oct
methyl
octane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012100016087A
Other languages
Chinese (zh)
Inventor
戴立言
袁更洋
王晓钟
陈英奇
宋晓晓
张玲玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHEJIANG SANHE PHARMACEUTICAL CHEMICAL CO Ltd
Zhejiang University ZJU
Original Assignee
ZHEJIANG SANHE PHARMACEUTICAL CHEMICAL CO Ltd
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHEJIANG SANHE PHARMACEUTICAL CHEMICAL CO Ltd, Zhejiang University ZJU filed Critical ZHEJIANG SANHE PHARMACEUTICAL CHEMICAL CO Ltd
Priority to CN2012100016087A priority Critical patent/CN102584814A/en
Publication of CN102584814A publication Critical patent/CN102584814A/en
Pending legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

本发明公开的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,依次包括如下步骤:以N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺为原料,在非质子溶剂中与硫化试剂加热回流得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺,然后与醇钠和卤代烃或硫酸酯反应得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯,接着在C2~C5的醇中与乙酰肼加热回流得8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷粗品,最后经正庚烷和乙酸乙酯精制得高纯度目标产品。采用本发明制备8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷避免了水对中间反应过程的干扰,收率高,产品纯度好。8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane disclosed in the present invention The preparation method of alkane comprises the steps successively: taking N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl) isobutyramide as raw material, in an aprotic solvent with a vulcanization reagent Heated to reflux to obtain N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide, then react with sodium alkoxide and halogenated hydrocarbon or sulfuric acid ester to obtain N-( 8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester, and then heated to reflux with acetylhydrazide in C2~C5 alcohol to obtain 8-benzyl- The crude product of 3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane was finally treated with n-heptane and Ethyl acetate was refined to obtain the high-purity target product. Adopt the present invention to prepare 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane The alkane avoids the interference of water on the intermediate reaction process, the yield is high, and the product purity is good.

Description

8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法Preparation method of 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane

技术领域 technical field

本发明涉及新型抗艾滋病药马拉维若(Maraviroc)的关键中间体8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法。 The invention relates to the key intermediate 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4- The preparation method of -8-azabicyclo [3.2.1] octane.

背景技术 Background technique

马拉维若(Maraviroc)2007年8月和9月分别获得美国FDA和欧盟委员会的批准,用于联用其它抗逆病毒药物治疗CCR5嗜性HIV-1感染患者,是迄今全球获准上市的第一个CCR5拮抗剂和第一个口服进入抑制剂,拥有显著的首入市场优势。8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷是新型抗艾滋病药马拉维若(Maraviroc)的关键中间体,目前合成此中间体的路线共同点是先将N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺氯化转化为N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁亚胺酸酰氯,再与乙酰肼反应转化为N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁亚胺酸酰肼,然后经环合获得8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷(WO2008063600;WO2010040272;Organic Process Research & Development 2008,12,1094–1103),不同文献的方法仅仅是路线的具体实施方式略有差别。由于N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁亚胺酸酰氯对水非常敏感,而乙酰肼吸水性很强,很难完全除去水分,所以反应中总有一部分N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁亚胺酸酰氯与乙酰肼中的水分反应转化为N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺氯,使得粗品8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷中含有7-8%的N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺氯。N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺氯的存在严重干扰了产品的重结晶,导致产品收率和纯度都偏低。 Maraviroc was approved by the US FDA and the European Commission in August and September 2007, respectively, for the treatment of patients with CCR5-tropic HIV-1 infection in combination with other antiretroviral drugs. A CCR5 antagonist and first oral entry inhibitor with significant first-to-market advantage. 8-Benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane is a new anti- The key intermediate of the AIDS drug Maraviroc, the current route to synthesize this intermediate has in common that N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl ) isobutyramide is converted into N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl) isobutyric acid chloride by chlorination, and then converted into N-( 8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyrimidic acid hydrazide, and then obtain 8-benzyl-3-(3-isopropyl-5 -Methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane (WO2008063600; WO2010040272; Organic Process Research & Development 2008,12,1094–1103) , the methods of different documents are only slightly different in the specific implementation of the route. Since N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyrimidic acid chloride is very sensitive to water, and acetylhydrazide is very absorbent, it is difficult to completely remove water , so there is always a part of N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl) isobutyrimidic acid chloride reacts with the moisture in acetylhydrazide to be converted into N-( 8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide chloride, so that the crude product 8-benzyl-3-(3-isopropyl-5-methyl-4H- 1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane contains 7-8% N-(8-benzyl-8-azabicyclo[3.2. 1] Oct-3-yl) isobutyramide chloride. The existence of N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide chloride seriously interferes with the recrystallization of the product, resulting in low product yield and purity.

发明内容 Contents of the invention

本发明的目的是提供一种避免了水对中间反应过程的干扰,收率高,产品纯度好的制备8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的方法。 The purpose of the present invention is to provide a method that avoids the interference of water to the intermediate reaction process, has high yield and good product purity to prepare 8-benzyl-3-(3-isopropyl-5-methyl-4H-1, 2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane method.

本发明8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,依次包括如下步骤:  8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane of the present invention The preparation method comprises the following steps in turn:

第一步 以N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺为原料,在非质子溶剂中与硫化试剂加热回流2~6h,减压蒸干,将所得固体用CH2Cl2和OH-水溶液溶解,并调节水层pH大于9,分出有机层,水层用CH2C2萃取,合并有机层,减压蒸干得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺,所用硫化试剂与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺摩尔比为0.3~0.6:1,所用非质子溶剂与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺重量比为5~10:1; The first step is to use N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide as raw material, heat and reflux with vulcanization reagent in an aprotic solvent for 2~6h, reduce Evaporate to dryness under pressure, dissolve the obtained solid with CH2Cl2 and OH - water solution, and adjust the pH of the aqueous layer to be greater than 9, separate the organic layer, extract the aqueous layer with CH2C2 , combine the organic layers, and evaporate to dryness under reduced pressure to obtain N -(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfuramide, the sulfurization reagent used is the same as N-(8-benzyl-8-azabicyclo[3.2 .1] Oct-3-yl)isobutyramide molar ratio is 0.3~0.6:1, the aprotic solvent used and N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl ) The weight ratio of isobutyramide is 5-10:1;

第二步 将第一步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺在醇钠的醇溶液中,与卤代烃或硫酸酯室温下反应5~8h,减压蒸馏,将所得黄色油状物用CH2Cl2和H2O溶解,分出有机层,水层用CH2Cl2萃取,合并有机层,有机层减压蒸干,得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯,所用醇钠与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺摩尔比为1.0~1.3:1,所用卤代烃或硫酸酯与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺摩尔比为1.0~1.2:1。 In the second step, N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl) isobutylsulfamide obtained in the first step is mixed with halogenated hydrocarbon in the alcoholic solution of sodium alkoxide Or react sulfuric acid ester at room temperature for 5-8 hours, distill under reduced pressure, dissolve the obtained yellow oil with CH 2 Cl 2 and H 2 O, separate the organic layer, extract the water layer with CH 2 Cl 2 , combine the organic layers, and the organic layer Evaporate to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester, sodium alkoxide and N-(8-benzyl Base-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide molar ratio is 1.0~1.3:1, halogenated hydrocarbon or sulfuric acid ester and N-(8-benzyl-8 -Azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide molar ratio is 1.0~1.2:1.

第三步  将第二步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯溶于C2~C5的醇中,然后与乙酰肼加热回流20~26h,减压蒸馏,将所得残余物用CH2Cl2和H2O溶解,分出有机层,水层用CH2Cl2萃取,合并有机层,有机层减压蒸馏得到8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷粗品,将此粗品溶于正庚烷和乙酸乙酯,加热至70~80℃,保温搅拌1.5~3h,冷却至室温,过滤,所用C2~C5醇与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯重量比为18~22:1,所用乙酰肼与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯摩尔比为1.5~2.5:1,所用正庚烷与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯重量比为2~5:1,所用乙酸乙酯与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯重量比为2~5:1。 The third step is to dissolve the N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester obtained in the second step in a C 2 ~C 5 alcohol , then heated to reflux with acetylhydrazide for 20-26h, distilled under reduced pressure, dissolved the resulting residue with CH 2 Cl 2 and H 2 O, separated the organic layer, extracted the water layer with CH 2 Cl 2 , combined the organic layers, and Layers were distilled under reduced pressure to obtain 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1] Octane crude product, this crude product is dissolved in n-heptane and ethyl acetate, heated to 70-80°C, kept stirring for 1.5-3h, cooled to room temperature, filtered, the C 2 ~C 5 alcohol used and N-(8-benzyl Base-8-azabicyclo[3.2.1]oct-3-yl)isobutyl imidic acid thioester weight ratio is 18~22:1, the acetylhydrazide and N-(8-benzyl-8- The molar ratio of azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester is 1.5~2.5:1, and the n-heptane and N-(8-benzyl-8-azabis The weight ratio of cyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester is 2~5:1, and the ethyl acetate and N-(8-benzyl-8-azabicyclo[3.2 .1] The weight ratio of oct-3-yl)isobutylimidic acid thioester is 2-5:1.

具体合成路线如下: Concrete synthetic route is as follows:

Figure 606880DEST_PATH_IMAGE001
Figure 606880DEST_PATH_IMAGE001

式中,R可以是CH3、CH3CH2、CH3CH2CH2、CH3CHCH3

Figure 256124DEST_PATH_IMAGE002
。 In the formula, R can be CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , CH 3 CHCH 3 or
Figure 256124DEST_PATH_IMAGE002
.

本发明制备方法中: In the preparation method of the present invention:

第一步所用的非质子溶剂为乙腈、甲苯、四氢呋喃、2-甲基四氢呋喃或甲基叔丁基醚;所用的硫化试剂为五硫化二磷或lawesson试剂; OH-水溶液为KOH水溶液或NaOH水溶液。 The aprotic solvent used in the first step is acetonitrile, toluene, tetrahydrofuran, 2-methyltetrahydrofuran or methyl tert-butyl ether; the vulcanization reagent used is phosphorus pentasulfide or lawesson reagent; the OH - water solution is KOH aqueous solution or NaOH aqueous solution.

第二步所用的醇钠的醇溶液为甲醇钠的甲醇溶液或乙醇钠的乙醇溶液,所用卤代烃为碘甲烷、碘乙烷、溴乙烷、氯乙烷、氯丙烷、溴丙烷、氯苄或溴苄;所用硫酸酯为硫酸甲酯或者硫酸乙酯。 The alcohol solution of sodium alkoxide used in the second step is methanol solution of sodium methoxide or ethanol solution of sodium ethoxide, and the halogenated hydrocarbon used is methyl iodide, ethyl iodide, ethyl bromide, ethyl chloride, chloropropane, bromopropane, chlorine Benzyl or bromobenzyl; the sulfate used is methyl sulfate or ethyl sulfate.

第三步所用C2~C5的醇为正丁醇、叔戊醇、异戊醇、正戊醇、乙醇、异丙醇、异丁醇或叔丁醇。 The C 2 -C 5 alcohol used in the third step is n-butanol, tert-amyl alcohol, isoamyl alcohol, n-amyl alcohol, ethanol, isopropanol, isobutanol or tert-butanol.

本发明以N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺为原料,经硫化、烃基化、环合制得8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷,操作简单,反应温和,避免了水对中间反应过程的干扰,收率较高,产品纯度好。 The present invention uses N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide as raw material to prepare 8-benzyl-3 -(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane, simple operation, mild reaction, avoiding Water interferes with the intermediate reaction process, the yield is high, and the product purity is good.

具体实施方式 Detailed ways

实施例1 Example 1

将N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺(2g,7mmol)和P2S5(0.47g,2.1mmol)混合,加入乙腈(12.6mL),加热回流6h,减压蒸干,将所得固体用CH2Cl2(20mL)和NaOH水溶液溶解,控制控制pH大于9,分出有机层,水层用CH2Cl2(10mLx2)萃取,合并有机层,减压蒸干得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺(1.99g,收率94.0%)。 Mix N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide (2g, 7mmol) and P2S5 ( 0.47g , 2.1mmol), add acetonitrile (12.6mL), heated to reflux for 6h, evaporated to dryness under reduced pressure, dissolved the obtained solid with CH 2 Cl 2 (20mL) and NaOH aqueous solution, controlled the pH to be greater than 9, separated the organic layer, and used CH 2 Cl 2 (10mLx2 ) extraction, the combined organic layers were evaporated to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide (1.99g, yield 94.0% ).

将Na(0.15g,6.6mmol)溶于甲醇(20mL),加N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺(2g,6.6mmol),全溶后加硫酸甲酯(0.83g,6.6mmol),室温搅拌,反应8h后减压蒸馏,将所得黄色油状物溶于CH2Cl2(50mL)和H2O(50mL),分出有机层,水层用CH2Cl2(50mLx2)萃取,合并有机层,有机层减压蒸干,得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸甲硫酯(2.03g,收率97.1%)。 Dissolve Na (0.15g, 6.6mmol) in methanol (20mL), add N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide (2g, 6.6mmol), after complete dissolution, add methyl sulfate (0.83g, 6.6mmol), stir at room temperature, react for 8h and distill under reduced pressure, dissolve the obtained yellow oil in CH 2 Cl 2 (50mL) and H 2 O (50mL) , the organic layer was separated, the aqueous layer was extracted with CH 2 Cl 2 (50mLx2), the organic layers were combined, and the organic layer was evaporated to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]octane -3-yl) methylthioisobutylimidate (2.03g, yield 97.1%).

将上步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸甲硫酯(2.09g,6.6mmol)和乙酰肼(0.73g,9.9mmol)溶于乙醇(44mL)、,加热回流26h,减压蒸馏,残余物加CH2Cl2(50mL)、H2O(50mL),分层,水层用CH2Cl2(50mLx2)萃取,合并有机层,减压蒸馏得黄色油状物8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷粗品,将此黄色油状物溶于正庚烷(14.7mL)和乙酸乙酯(4.5mL),加热至70℃,保温搅拌1.5h,冷却至室温,过滤得固体为高纯度的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷(1.75g,收率81.9%)。 N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid methylthio ester (2.09g, 6.6mmol) and acetylhydrazine (0.73 g, 9.9mmol) was dissolved in ethanol (44mL), heated to reflux for 26h, and distilled under reduced pressure. The residue was added with CH 2 Cl 2 (50mL) and H 2 O (50mL), and the layers were separated. The water layer was washed with CH 2 Cl 2 ( 50mLx2) extraction, combined the organic layers, and distilled under reduced pressure to obtain the yellow oil 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)- Crude 8-azabicyclo[3.2.1]octane, the yellow oil was dissolved in n-heptane (14.7mL) and ethyl acetate (4.5mL), heated to 70°C, kept stirring for 1.5h, cooled to room temperature , and the filtered solid was high-purity 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2 .1] Octane (1.75 g, 81.9% yield).

实施例2 Example 2

将N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺(2g,7mmol)和Lawesson试剂(1.27g,3.2mmol)混合,加入四氢呋喃(16.8mL),加热回流4h,减压蒸干,将所得固体用CH2Cl2(20mL)和KOH水溶液溶解,控制控制pH大于9,分出有机层,水层用CH2Cl2(10mLx2)萃取,合并有机层,减压蒸干得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺(2.04g,收率96.3%)。 N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide (2g, 7mmol) and Lawesson's reagent (1.27g, 3.2mmol) were mixed, tetrahydrofuran (16.8 mL), heated to reflux for 4h, evaporated to dryness under reduced pressure, dissolved the obtained solid with CH 2 Cl 2 (20mL) and KOH aqueous solution, controlled the pH to be greater than 9, separated the organic layer, and extracted the aqueous layer with CH 2 Cl 2 (10mLx2) , combined the organic layers, and evaporated to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide (2.04g, yield 96.3%).

将Na(0.18g,7.6mmol)溶于乙醇(20mL),加N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺(2g,6.6mmol),全溶后加氯化苄(0.92g,7.3mmol),室温搅拌,反应6h后减压蒸馏,将所得黄色油状物溶于CH2Cl2(50mL)和H2O(50mL),分出有机层,水层用CH2Cl2(50mLx2)萃取,合并有机层,有机层减压蒸干,得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸苄硫酯粗品(2.53g,收率97.8%)。 Dissolve Na (0.18g, 7.6mmol) in ethanol (20mL), add N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide (2g, 6.6mmol), add benzyl chloride (0.92g, 7.3mmol) after complete dissolution, stir at room temperature, react for 6h and distill under reduced pressure, dissolve the obtained yellow oil in CH 2 Cl 2 (50mL) and H 2 O (50mL) , the organic layer was separated, the aqueous layer was extracted with CH 2 Cl 2 (50mLx2), the organic layers were combined, and the organic layer was evaporated to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]octane -3-yl) crude product of benzylthioisobutylimidate (2.53g, yield 97.8%).

将上步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸苄硫酯(2.59g,6.6mmol)和乙酰肼(0.98g,13.2mmol)溶于异丙醇(51mL)、,加热回流24h,减压蒸馏,残余物加CH2Cl2(50mL)、H2O(50mL),分层,水层用CH2Cl2(50mLx2)萃取,合并有机层,减压蒸馏得黄色油状物8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷粗品,将此黄色油状物溶于正庚烷(10.3mL)和乙酸乙酯(7.8mL),加热至75℃,保温搅拌3h,冷却至室温,过滤得固体为高纯度的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷(1.77g,收率82.8%)。 N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid benzylthioester (2.59g, 6.6mmol) and acetylhydrazide (0.98 g, 13.2mmol) was dissolved in isopropanol (51mL), heated to reflux for 24h, distilled under reduced pressure, the residue was added with CH 2 Cl 2 (50mL), H 2 O (50mL), the layers were separated, and the aqueous layer was washed with CH 2 Cl 2 (50mLx2) extraction, combined the organic layers, and distilled under reduced pressure to give yellow oil 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl )-8-Azabicyclo[3.2.1]octane crude product, the yellow oil was dissolved in n-heptane (10.3mL) and ethyl acetate (7.8mL), heated to 75°C, kept stirring for 3h, cooled to At room temperature, the solid obtained by filtration was high-purity 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[ 3.2.1] Octane (1.77g, yield 82.8%).

实施例3 Example 3

将N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺(2g,7mmol)和P2S5(0.93g,4.2mmol)混合,加入甲苯(23mL),加热回流2h,减压蒸干,将所得固体用CH2Cl2(20mL)和KOH水溶液溶解,控制控制pH大于9,分出有机层,水层用CH2C2(10mLx2)萃取,合并有机层,减压蒸干得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺(2.02g,收率95.6%)。 Mix N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide (2g, 7mmol) and P2S5 ( 0.93g , 4.2mmol), add toluene (23mL), heated to reflux for 2h, evaporated to dryness under reduced pressure, dissolved the obtained solid with CH 2 Cl 2 (20mL) and KOH aqueous solution, controlled the pH to be greater than 9, separated the organic layer, and used CH 2 C 2 (10mLx2) for the aqueous layer Extract, combine the organic layers, and evaporate to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide (2.02g, yield 95.6%) .

将Na(0.2g,8.6mmol)溶于甲醇(20mL),加N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺(2g,6.6mmol),全溶后加碘甲烷(1.22g,8.6mmol),室温搅拌,反应5h后减压蒸馏,将所得黄色油状物溶于CH2Cl2(50mL)和H2O(50mL),分出有机层,水层用CH2Cl2(50mLx2)萃取,合并有机层,有机层减压蒸干,既得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸甲硫酯粗品(2.05g,收率98.2%)。 Dissolve Na (0.2g, 8.6mmol) in methanol (20mL), add N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide (2g, 6.6mmol), after complete dissolution, add iodomethane (1.22g, 8.6mmol), stir at room temperature, react for 5h and distill under reduced pressure, dissolve the obtained yellow oil in CH 2 Cl 2 (50mL) and H 2 O (50mL), Separate the organic layer, extract the aqueous layer with CH 2 Cl 2 (50mLx2), combine the organic layers, and evaporate the organic layer to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]octyl- 3-yl) crude product of methylthioisobutylimidate (2.05g, yield 98.2%).

将上步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸甲硫酯(2.59g,6.6mmol)和乙酰肼(1.22g,16.5mmol)溶于正戊醇(54mL),加热回流20h,减压蒸馏,残余物加CH2Cl2(50mL)、H2O(50mL),分层,水层用CH2Cl2(50mLx2)萃取,合并有机层,减压蒸馏得黄色油状物8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷粗品,将此黄色油状物溶于正庚烷(5.9mL)和乙酸乙酯(11mL),加热至80℃,保温搅拌2h,冷却至室温,过滤得固体为高纯度的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷(1.75g,收率81.8%)。 N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid methylthio ester (2.59g, 6.6mmol) and acetylhydrazide (1.22 g, 16.5mmol) was dissolved in n-pentanol (54mL), heated to reflux for 20h, and distilled under reduced pressure. The residue was added with CH 2 Cl 2 (50mL) and H 2 O (50mL), and the layers were separated. The water layer was washed with CH 2 Cl 2 (50mLx2) extraction, combined organic layers, and distillation under reduced pressure to obtain a yellow oily substance 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl) - Crude 8-azabicyclo[3.2.1]octane, the yellow oil was dissolved in n-heptane (5.9mL) and ethyl acetate (11mL), heated to 80°C, kept stirring for 2h, cooled to room temperature, The solid obtained by filtration is high-purity 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2. 1] Octane (1.75g, yield 81.8%).

Claims (7)

1.8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,依次包括如下步骤: 1. The preparation method of 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane , including the following steps in turn: 第一步 以N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺为原料,在非质子溶剂中与硫化试剂加热回流2~6h,减压蒸干,将所得固体用CH2Cl2和OH-水溶液溶解,并调节水层pH大于9,分出有机层,水层用CH2C2萃取,合并有机层,减压蒸干得到N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺,所用硫化试剂与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺摩尔比为0.3~0.6:1,所用非质子溶剂与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁酰胺重量比为5~10:1; The first step is to use N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutyramide as raw material, heat and reflux with vulcanization reagent in an aprotic solvent for 2~6h, reduce Evaporate to dryness under pressure, dissolve the obtained solid with CH2Cl2 and OH - water solution, and adjust the pH of the aqueous layer to be greater than 9, separate the organic layer, extract the aqueous layer with CH2C2 , combine the organic layers, and evaporate to dryness under reduced pressure to obtain N -(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfuramide, the sulfurization reagent used is the same as N-(8-benzyl-8-azabicyclo[3.2 .1] Oct-3-yl)isobutyramide molar ratio is 0.3~0.6:1, the aprotic solvent used and N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl ) The weight ratio of isobutyramide is 5-10:1; 第二步 将第一步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺在醇钠的醇溶液中,与卤代烃或硫酸酯室温下反应5~8h,减压蒸馏,将所得黄色油状物用CH2Cl2和H2O溶解,分出有机层,水层用CH2Cl2萃取,合并有机层,有机层减压蒸干,得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯,所用醇钠与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺摩尔比为1.0~1.3:1,所用卤代烃或硫酸酯与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基硫酰胺摩尔比为1.0~1.2:1; In the second step, N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl) isobutylsulfamide obtained in the first step is mixed with halogenated hydrocarbon in the alcoholic solution of sodium alkoxide Or react sulfuric acid ester at room temperature for 5-8 hours, distill under reduced pressure, dissolve the obtained yellow oil with CH 2 Cl 2 and H 2 O, separate the organic layer, extract the water layer with CH 2 Cl 2 , combine the organic layers, and the organic layer Evaporate to dryness under reduced pressure to obtain N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester, sodium alkoxide and N-(8-benzyl Base-8-azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide molar ratio is 1.0~1.3:1, halogenated hydrocarbon or sulfuric acid ester and N-(8-benzyl-8 -Azabicyclo[3.2.1]oct-3-yl)isobutylsulfamide molar ratio is 1.0~1.2:1; 第三步  将第二步所得N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯溶于C2~C5的醇中,然后与乙酰肼加热回流20~26h,减压蒸馏,将所得残余物用CH2Cl2和H2O溶解,分出有机层,水层用CH2Cl2萃取,合并有机层,有机层减压蒸馏得到8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷粗品,将此粗品溶于正庚烷和乙酸乙酯,加热至70~80℃,保温搅拌1.5~3h,冷却至室温,过滤,所用C2~C5醇与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯重量比为18~22:1,所用乙酰肼与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯摩尔比为1.5~2.5:1,所用正庚烷与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯重量比为2~5:1,所用乙酸乙酯与N-(8-苄基-8-氮杂二环[3.2.1]辛-3-基)异丁基亚胺酸硫酯重量比为2~5:1。 The third step is to dissolve the N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester obtained in the second step in a C 2 ~C 5 alcohol , then heated to reflux with acetylhydrazide for 20-26h, distilled under reduced pressure, dissolved the resulting residue with CH 2 Cl 2 and H 2 O, separated the organic layer, extracted the water layer with CH 2 Cl 2 , combined the organic layers, and Layers were distilled under reduced pressure to obtain 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1] Octane crude product, this crude product is dissolved in n-heptane and ethyl acetate, heated to 70-80°C, kept stirring for 1.5-3h, cooled to room temperature, filtered, the C 2 ~C 5 alcohol used and N-(8-benzyl Base-8-azabicyclo[3.2.1]oct-3-yl)isobutyl imidic acid thioester weight ratio is 18~22:1, the acetylhydrazide and N-(8-benzyl-8- The molar ratio of azabicyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester is 1.5~2.5:1, and the n-heptane and N-(8-benzyl-8-azabis The weight ratio of cyclo[3.2.1]oct-3-yl)isobutylimidic acid thioester is 2~5:1, and the ethyl acetate and N-(8-benzyl-8-azabicyclo[3.2 .1] The weight ratio of oct-3-yl)isobutylimidic acid thioester is 2-5:1. 2.按权利要求1所述的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,其特征在于第一步所用的非质子溶剂为乙腈、甲苯、四氢呋喃、2-甲基四氢呋喃或甲基叔丁基醚。 2. 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-yl)-8-azabicyclo[ 3.2.1] The preparation method of octane is characterized in that the aprotic solvent used in the first step is acetonitrile, toluene, tetrahydrofuran, 2-methyltetrahydrofuran or methyl tert-butyl ether. 3.按权利要求1所述的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,其特征在于第一步所用的硫化试剂为五硫化二磷或lawesson试剂。 3. 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-yl)-8-azabicyclo[ 3.2.1] the preparation method of octane is characterized in that the vulcanization reagent used in the first step is phosphorus pentasulfide or lawesson reagent. 4.按权利要求1所述的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,其特征在于第一步所用的OH-水溶液为KOH水溶液或NaOH水溶液。 4. 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-yl)-8-azabicyclo[ 3.2.1] The preparation method of octane is characterized in that the OH - water solution used in the first step is KOH aqueous solution or NaOH aqueous solution. 5.按权利要求1所述的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,其特征在于第二步所用的醇钠的醇溶液为甲醇钠的甲醇溶液或乙醇钠的乙醇溶液。 5. 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-yl)-8-azabicyclo[ 3.2.1] the preparation method of octane is characterized in that the alcoholic solution of sodium alkoxide used in the second step is the methanol solution of sodium methylate or the ethanol solution of sodium ethylate. 6.按权利要求1所述的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,其特征在于第二步所用卤代烃为碘甲烷、碘乙烷、溴乙烷、氯乙烷、氯丙烷、溴丙烷、氯苄或溴苄,所用硫酸酯为硫酸甲酯或者硫酸乙酯。 6. 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-yl)-8-azabicyclo[ 3.2.1] the preparation method of octane is characterized in that the halogenated hydrocarbon used in the second step is methyl iodide, ethyl iodide, ethyl bromide, ethyl chloride, chloropropane, bromopropane, benzyl chloride or bromobenzyl, and the used sulfuric acid The ester is methyl sulfate or ethyl sulfate. 7.按权利要求1所述的8-苄基-3-(3-异丙基-5-甲基-4H-1,2,4-三唑-4-基)-8-氮杂双环[3.2.1]辛烷的制备方法,其特征在于第三步所用C2~C5的醇为正丁醇、叔戊醇、异戊醇、正戊醇、乙醇、异丙醇、异丁醇或叔丁醇。 7. 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-yl)-8-azabicyclo[ 3.2.1] The preparation method of octane is characterized in that the alcohol of C2C5 used in the third step is n-butanol, tert-amyl alcohol, isoamyl alcohol, n-amyl alcohol, ethanol, isopropanol, isobutanol or tert-butanol.
CN2012100016087A 2012-01-05 2012-01-05 Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane Pending CN102584814A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012100016087A CN102584814A (en) 2012-01-05 2012-01-05 Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012100016087A CN102584814A (en) 2012-01-05 2012-01-05 Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane

Publications (1)

Publication Number Publication Date
CN102584814A true CN102584814A (en) 2012-07-18

Family

ID=46474134

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012100016087A Pending CN102584814A (en) 2012-01-05 2012-01-05 Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane

Country Status (1)

Country Link
CN (1) CN102584814A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556899B2 (en) * 2018-02-09 2020-02-11 Sci Pharmtech, Inc. Method for preparing Maraviroc

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073221A1 (en) * 2004-01-16 2005-08-11 Bristol-Myers Squibb Company HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
WO2006090270A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Acid addition salt of 2-isopropyl-4-(((n-methyl)amino)methyl)thiazole and its?use in the preparation of ritonavir
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
WO2010040272A1 (en) * 2008-10-08 2010-04-15 中国科学院上海药物研究所 Amide compounds, their pharmaceutical compositions, their preparation and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073221A1 (en) * 2004-01-16 2005-08-11 Bristol-Myers Squibb Company HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
WO2006090270A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Acid addition salt of 2-isopropyl-4-(((n-methyl)amino)methyl)thiazole and its?use in the preparation of ritonavir
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
WO2010040272A1 (en) * 2008-10-08 2010-04-15 中国科学院上海药物研究所 Amide compounds, their pharmaceutical compositions, their preparation and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAH J. HAYCOCK-LEWANDOWSKI 等: "Development of a Bulk Enabling Route to Maraviroc (UK-427,857), a CCR-5 Receptor Antagonist", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556899B2 (en) * 2018-02-09 2020-02-11 Sci Pharmtech, Inc. Method for preparing Maraviroc

Similar Documents

Publication Publication Date Title
AU2014304562B8 (en) Thieno[2,3-c]pyrans as CFTR modulators
EP2220095B1 (en) Inhibitors of human immunodeficiency virus replication
US8461180B2 (en) Inhibitors of human immunodeficiency virus replication
CN104496983A (en) Palbociclib preparation method
KR20200136493A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
US20140206657A1 (en) Bile acid analog tgr5 agonists
WO2013040534A1 (en) Substituted 1h-pyrazolo[3',4',4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulatiors of the muscarinic acetycholine receptor m4
EP2220076A1 (en) Inhibitors of human immunodeficiency virus replication
JP7419575B2 (en) Fused ring indazole compounds
WO2011163280A1 (en) Indole compounds as positive allosteric modulators of the muscarinic receptor
CN105085533A (en) Novel crystal form of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridine-2-yl amino)-7H-pyrrolo [2,3-D] pyrimidine-6-carboxylic acid dimethylamide single succinate
US10246481B2 (en) Bile acid derivatives and methods for synthesis and use
US20230065034A1 (en) Crf receptor antagonists and methods of use
JP6950092B2 (en) Salt of setagliptin and its production method, drug composition, and its use
CN102746276B (en) Ilaprazole sodium crystal form and preparation method thereof
CN102584814A (en) Preparation method for 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazole-4-base)-8-azabicyclo[3.2.1]octane
WO2014187273A1 (en) Avanafil preparation method
CN105503927B (en) Method for synthesizing 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester
CN105683186A (en) An industrially applicable process for preparing high purity aclidinium bromide
Mei et al. Synthesis of diazonium (perfluoroalkyl) benzenesulfonylimide zwitterions
CN109232301A (en) A kind of preparation method of the tetra isopropyl hydrazine of low cost and high yield
CN104292213A (en) Preparation method of pyrimidine derivative
CN109678812B (en) Preparation method of 5-vinyl-2-thiooxazolidine
CN102070624A (en) Method for synthesizing tiagabine hydrochloride and method for preparing anhydrous tiagabine hydrochloride
CN102264735A (en) One-step process for preparing paliperidone and its oxalate salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120718